Rating Change
Wedbush reiterated its Outperform rating on Fate Therapeutics, Inc. (NASDAQ:FATE) on October 27, 2026.
reiterateNASDAQ:FATE
Wedbush Reiterates Outperform Rating on Fate Therapeutics, Inc. (FATE)
Wedbush reiterated its Outperform rating on Fate Therapeutics, Inc. (NASDAQ:FATE) on October 27, 2026.
At publication ·
What changed
Fate Therapeutics, Inc. (NASDAQ:FATE) · reiterate
- Firm
- Wedbush
- Rating
- Outperform to Outperform
- Price at event
- $2.07
- Market capitalization
- $128.0M
At a glance
Key takeaways
- Wedbush reiterated an Outperform rating on Fate Therapeutics on October 27, 2026, with the stock trading at $2.07 and a market cap of $128.0 million.
Market Context
Fate Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $2.07 with a market capitalization of $128.0M. The stock has gained 35.2% over the past 52 weeks.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Fate Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Fate Therapeutics, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 27, 2026 | Wedbush | Outperform | N/A |
| Aug 14, 2026 | Wells Fargo | Equal-Weight | N/A |
| Aug 14, 2026 | Piper Sandler | Overweight | N/A |
| Aug 14, 2026 | Wedbush | Outperform | N/A |
| Jun 08, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View FATE Stock Page
Frequently Asked Questions
What does the Outperform rating mean for FATE?
A rating of Outperform from Wedbush reflects the analyst's outlook on Fate Therapeutics, Inc. (NASDAQ:FATE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the FATE forecast page.